{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.843","value":"12.0"},{"groupId":"OG001","spread":"17.616","value":"12.0"},{"groupId":"OG002","spread":"9.032","value":"13.75"},{"groupId":"OG003","spread":"9.049","value":"1.10"},{"groupId":"OG004","spread":"10.909","value":"9.0"},{"groupId":"OG005","spread":"18.574","value":"15.50"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"4"}],"units":"Participants"}],"description":"Anti-tumor activity measured by tumor shrinkage was evaluated on based on of sum of the diameter(s) of all target lesions from the computerized tomography (CT) scan/positron emission tomography (PET)-CT scan. Largest tumor shrinkage is reported.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received 0.1 mg/kg of GEN1029 every 2 weeks (Q2W) until the end of treatment.","id":"OG000","title":"Biweekly Regimen (GEN1029 0.1 mg/kg)"},{"description":"Participants received 0.2 mg/kg of GEN1029 Q2W until the end of treatment.","id":"OG001","title":"Biweekly Regimen (GEN1029 0.2 mg/kg)"},{"description":"Participants received 0.3 mg/kg of GEN1029 Q2W until the end of treatment.","id":"OG002","title":"Biweekly Regimen (GEN1029 0.3 mg/kg)"},{"description":"Participants received 1.0 mg/kg of GEN1029 Q2W until the end of treatment.","id":"OG003","title":"Biweekly Regimen (GEN1029 1.0 mg/kg)"},{"description":"Participants received 2.0 mg/kg of GEN1029 Q2W until the end of treatment.","id":"OG004","title":"Biweekly Regimen (GEN1029 2.0 mg/kg)"},{"description":"Participants received 3.0 mg/kg of GEN1029 Q2W until the end of treatment.","id":"OG005","title":"Biweekly Regimen (GEN1029 3.0 mg/kg)"}],"paramType":"MEAN","populationDescription":"Full analysis set included all participants who received at least one dose of GEN1029 and were analyzed according to the actual treatment received.","reportingStatus":"POSTED","timeFrame":"From Baseline (Day 1) through 8.8 months (corresponding to maximum observed duration)","title":"Change From Baseline in Anti-tumor Activity Measured by Tumor Shrinkage","type":"SECONDARY","unitOfMeasure":"millimeter"}